CIBC Bancorp USA’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARQT
CIBC Bancorp USA's ARQT Position: Q3 2026 in Review
CIBC Bancorp USA increased its Arcutis Biotherapeutics (ARQT) stake by 36% in Q3 2026, buying an estimated $140K and bringing the position to 20,113 shares worth $531K. The position accounts for ﹤0.01% of the portfolio, ranked #1338.
CIBC Bancorp USA first reported a position in ARQT in Q3 2025 and has held it in 4 quarters since. 294 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.
- CIBC Bancorp USA held 20,113 shares of Arcutis Biotherapeutics worth $531K as of Q3 2026.
- CIBC Bancorp USA bought 5,354 Arcutis Biotherapeutics shares in Q3 2026, an estimated $140K.
- Arcutis Biotherapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1338 holding.
- CIBC Bancorp USA first reported a position in Arcutis Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
- 294 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.
Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.